The results of tumor tissue immunohistochemistry revealed that 7.3% of ICC and 5.2% of hilar or distal cholangiocarcinoma tested positive of PD‐L1,10 suggesting the potential benefit of immunotherapy in BTC. Here, CD274 is linked to intrahepatic cholangiocarcinoma.